Mylan's Herceptin Advisory Committee May Be First Bumpy One For A Biosimilar
Executive Summary
US FDA did not address production problems in its briefing document for upcoming Oncologic Drugs Advisory Committee meeting, but manufacturing deficiencies found at Biocon's facility could prompt questions.
You may also be interested in...
Biosimilarity Margin Change By FDA Might Give Amgen's Avastin Copy Big Head Start
Did Amgen/Allergan get a lucky break by already having their clinical trial enrolled and being unable to increase the sample size for their Avastin biosimilar?
Biosimilarity Margin Change By FDA Might Give Amgen's Avastin Copy Big Head Start
Did Amgen/Allergan get a lucky break by already having their clinical trial enrolled and being unable to increase the sample size for their Avastin biosimilar?
Will GMP Lapses Stall Biocon-Mylan’s Biosimilars Build-Up?
Compliance deviations flagged by French regulator ANSM at Biocon’s Indian site have raised questions around commercialization timelines in the EU for the firm and partner Mylan’s biosimilars, including trastuzumab. The news comes ahead of an FDA advisory panel review later this week for the product. Biocon, though, appears confident of setting compliance woes right quickly.